P/B
4,1
Aclaris Therapeutics
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
$513.7M
Market Cap • 10/15/2026
2012
(14 years)
Founded
2015
(11 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
62,5
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,8
EPS
—
Market Cap
Market Cap
513,7M
EV
422,2M
EV/Revenue
51,4
EV/EBITDA
-4,9
EV/EBIT
-4,9
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0,1%
Total Yield
0,1%
Payout
0%
Retained Earnings
-1B
Profitability
Gross Margin
79,5%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
770,6%
Capex/Revenue
1,4%
Capex/D&A
28%
Capex/OCF
-0,2%
SBC/OCF
—
% PPE
0,4%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
4,4%
CAGR Op. Income 5Y
4,1%
CAGR Net Income 5Y
1,3%
CAGR EPS 5Y
-16,9%
CAGR OCF 5Y
6,4%
Leverage
N.D./EBITDA
1,1
Debt/Equity
0%
Current Ratio
3,5
Quick Ratio
3,5
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!